Product Name: Sunifiram powder / DM-235
Synonyms: 1-benzoyl-4-(1-oxopropyl)-; SunifiraM; 1-(4-Benzoyl-1-piperazinyl)-1-propanone; 1-Benzoyl-4-(1-oxopropyl)-piperazine; 1-(4-Benzoylpiperazin-1-yl)propan-1-one; 1-Benzoyl-4-propanoylpiperazine
CAS: 314728-85-3
MF: C14H18N2O2
MW: 246.30492
Appearance: White powder
Purity: 99.32%
Shelf life: 2 years
Standard: In-house Standard
Usage: For the treatment of Alzheimers Dementia, Cognition Disorder, Neurologic Drugs, Senile Dementia, Acetylcholine Release Enhancers.

Sunifiram (DM-235) is a piperazine derived research chemical which has anti-amnesiac effects in animal studies with significantly higher potency than piracetam. Sunifiram is a molecular simplification of unifiram. Based on in vitro and animal studies, it appears that sunifiram acts via AMPA-receptor activation.

Sunifiram operates by activating AMPA receptors; that is, the receptors that are responsible for the mediation of synaptic transmission in the central nervous system. Its mechanics also increases phosphorylation of AMPAR and NMDAR through protein kinase activation, which in turn enhances long-term potentiation - that is, an enhancement in signal transmission between two neurons resulting from simultaneous stimulation.
The kinase activation that is influenced by Sunifiram also improves cognitive defects. Additionally, Sunifiram works in the cerebral cortex of animal test subjects by assisting in the release of acetylcholine, the organic molecule that acts as a neurotransmitter in a host of various organisms. These operational mechanisms enable Sunifiram to exert anti-amnesiac properties.